Close Menu

Ambry

Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.

The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.  

The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.

Many companies and counselors see the COVID-19 pandemic as a catalyst for moving germline risk testing into a digital-first healthcare model.

The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.

Clinical sequencing consumables revenues grew 20 percent year over year and accounted for just over 40 percent of total consumables shipments in 2019.

Currently available under a soft launch, the tool can provide information about the prevalence of cancer risk mutations based on patients' demographics.

The company's +RNAinsight test, a combined DNA and RNA genetic test for hereditary cancer syndromes, was launched in October.

The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.

The researchers estimated that addition of RNA-based testing could benefit about 1 in 43 individuals undergoing hereditary cancer predisposition genetic testing.

Pages

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.